Clinical implications of the genetics of ALS and other motor neuron diseases

Neurology

Volumn 57, Issue 1, 2001, Pages 9-17

  Orrell, Richard W ^a   Figlewicz, Denise A ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; AUTOSOMAL DOMINANT INHERITANCE; GANGLIOSIDOSIS; GENE CLUSTER; GENE MUTATION; GENETIC LINKAGE; GENETIC SCREENING; GENETICS; HUMAN; MOLECULAR GENETICS; MOTOR NEURON DISEASE; MULTIGENE FAMILY; PRIORITY JOURNAL; REVIEW; TELOMERE; TRINUCLEOTIDE REPEAT;

EID: 0035838427     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.57.1.9     Document Type: Review

References (81)

1. Potential role of an additive genetic component in the cause of amyotrophic lateral sclerosis and parkinsonism-dementia in the Western Pacific
2. Identification of flanking markers for the familial amyotrophic lateral sclerosis gene ALS1 on chromosome 21
3. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis
4. Amyotrophic lateral sclerosis: Copper/zinc superoxide dismutase (SOD1) gene mutations
5. Clinical and functional investigation of 10 missense mutations and a novel frameshift insertion mutation of the gene for copper-zinc superoxide dismutase in UK families with amyotrophic lateral sclerosis
6. Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis
7. Autosomal recessive adult-onset amyotrophic lateral sclerosis associated with-homozygosity for Asp90A1a CuZn-superoxide dismutase mutation
8. Difficulties in distinguishing sporadic from familial amyotrophic lateral sclerosis
9. The Cu/Zn superoxide dismutase gene in ALS and parkinsonism-dementia of Guam
10. Clinical characteristics of SOD1 gene mutations in UK families with ALS
11. Phenotypic heterogeneity in motor neuron disease patients with CuZn-superoxide dismutase mutations in Scandinavia
12. Amyotrophic lateral sclerosis associated with genetic abnormalities in the gene encoding Cu/Zn superoxide dismutase: Molecular pathology of five new cases, and comparison with previous reports and 73 sporadic cases of ALS
13. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation
14. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions
15. Amyotrophic lateral sclerosis and Alzheimer's disease. Lessons from model systems
16. Superoxide dismutase and neurofilament transgenic models of amyotrophic lateral sclerosis
17. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis
18. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis
19. Therapeutic benefits of putrescine-modified catalase in a transgenic mouse model of familial amyotrophic lateral sclerosis
20. The copper chelator D-penicillamine delays onset of disease and extends survival in a transgenic mouse model of familial amyotrophic lateral sclerosis
21. Benefit of a combined treatment with trientine and ascorbate in familial amyotrophic lateral sclerosis model mice
22. Beneficial effects of lysine acetylsalicylate, a soluble salt of aspirin, on motor performance in a transgenic model of amyotrophic lateral sclerosis
23. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model
24. Bcl-2: Prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis
25. Dose-ranging study of riluzole in amyotrophic lateral sclerosis
26. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) (Cochrane review)
27. Intramuscular grafts of myoblasts genetically modified to secrete glial cell line-derived neurotrophic factor prevent motoneuron loss and disease progression in a mouse model of familial amyotrophic lateral sclerosis
28. Increased motoneuron survival and improved neuromuscular function in transgenic ALS mice after intraspinal injection of adeno-associated virus encoding Bcl-2
29. From Charcot to SOD1: Mechanisms of selective motor neuron death in ALS
30. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis
31. Motor neurons are selectively vulnerable to AMPA/kainate receptor-mediated injury in vitro
32. Calcium-permeable AMPA receptors: A molecular determinant of selective vulnerability in amyotrophic lateral sclerosis
33. Rapid Ca entry through Ca-permeable AMPA/kainate channels triggers marked intracellular Ca rises and consequent oxygen radical production
34. Intracellular calcium parallels motoneuron degeneration in SOD-1 mutant mice
35. Glutamate potentiates the toxicity of mutant Cu/Zn-superoxide dismutase in motor neurons by postsynaptic calcium-dependent mechanisms
36. ALS-linked Cu/Zn-SOD mutation increases vulnerability of motor neurons to excitotoxicity by a mechanism involving increased oxidative stress and perturbed calcium homeostasis
37. Refined mapping and characterization of the recessive familial amyotrophic lateral sclerosis locus on chromosome 2q33
38. Linkage of a commoner form of recessive amyotrophic lateral sclerosis to chromosome 15q15-q22
39. Linkage of the gene for an autosomal dominant form of juvenile amyotrophic lateral sclerosis to chromosome 9q34
40. Linkage of familial amyotrophic lateral sclerosis with frontotemporal dementia to chromosome 9q21-q22
41. Association of missense and 5-prime splice site mutations in tau with the inherited dementia FTDP-17
42. Absence of mutations in the Mn superoxide dismutase or catalase genes in familial amyotrophic lateral sclerosis
43. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis
44. Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis
45. Late onset death of motor neurons in mice overexpressing wild-type peripherin
46. Aberrant RNA processing in a neurodegenerative disease: A common cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis
47. Identification of alternative splicing forms of GLT-1 mRNA in the spinal cord of amyotrophic lateral sclerosis patients
48. The RNA of the glutamate transporter EAAT2 is variably spliced in amyotrophic lateral sclerosis and normal individuals
49. Association of apolipoprotein E epsilon 4 allele with bulbar-onset motor neuron disease
50. Cytochrome c oxidase subunit 1 microdeletion in a patient with motor neuron disease
51. Analysis of chromosome 5q13 genes in amyotrophic lateral sclerosis: Homozygous NAIP deletion in a sporadic case
52. Mutant AP endonuclease in patients with amyotrophic lateral sclerosis
53. Molecular genetic analysis of the APEX nuclease gene in amyotrophic lateral sclerosis
54. Motor neuron disease and adult hexosaminidase A deficiency in two families: Evidence for multisystem degeneration
55. Tay-Sachs disease-causing mutations and neutral polymorphisms in the Hex A gene
56. Identification and characterization of a spinal muscular atrophy-determining gene
57. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2
58. The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy
59. A novel function for SMN, the spinal muscular atrophy disease gene product, in pre-mRNA splicing
60. The relationship between SMN, the spinal muscular atrophy protein, and nuclear coiled bodies in differentiated tissues and cultured cells
61. Gemin4: A novel component of the SMN complex that is found in both gems and nucleoli
62. Specific sequences of the Sm and Sm-like (Lsm) proteins mediate their interaction with the spinal muscular atrophy disease gene product (SMN)
63. Characterization of a nuclear 20S complex containing the survival of motor neurons (SMN) protein and a specific subset of spliceosomal Sm proteins
64. Reduced survival motor neuron (SMN) gene dose in mice leads to motor neuron degeneration: An animal model for spinal muscular atrophy type III
65. 59th ENMC International Workshop: Spinal muscular atrophies: Recent progress and revised diagnostic criteria
66. SMN gene deletions in adult-onset spinal muscular atrophy
67. The relationship of spinal muscular atrophy to motor neuron disease: Investigation of SMN and NAIP gene deletions in sporadic and familial ALS
68. Deletions causing spinal muscular atrophy do not predispose to amyotrophic lateral sclerosis
69. Cleavage, aggregation and toxicity of the expanded androgen receptor in spinal and bulbar muscular atrophy
70. Severity of X-linked recessive bulbospinal neuronopathy correlates with the size of the tandem CAG repeat in androgen receptor gene
71. Androgen receptor gene polymorphisms in amyotrophic lateral sclerosis
72. Spinobulbar muscular atrophy can mimic ALS: The importance of genetic testing in male patients with atypical ALS
73. "Pure" hereditary spastic paraplegias: The stow becomes complicated
74. Genetic mapping to 10q23.3-q24.2, in a large Italian pedigree, of a new syndrome showing bilateral cataracts, gastroesophageal reflux, and spastic paraparesis with amyotrophy
75. A new locus for autosomal dominant pure hereditary spastic paraplegia mapping to chromosome 12q13, and evidence for further genetic heterogeneity
76. A locus for autosomal dominant pure hereditary spastic paraplegia maps to chromosome 19q13
77. A new locus for autosomal dominant pure spastic paraplegia, on chromosome 2q24-q34
78. A new locus for autosomal recessive spastic paraplegia associated with mental retardation and distal motor neuropathy, SPG 14, maps to chromosome 3q27-q28
79. Spastin, a new AAA protein, is altered in the most frequent form of autosomal dominant spastic paraplegia
80. A. Spastic paraplegia and OXPHOS impairment caused by mutations in paraplegin, a nuclear-encoded mitochondrial metalloprotease
81. Phenotypic and genotypic heterogeneity in hereditary motor neuronopathy type V